ClinicalTrials.gg
Not yet recruitingNCT07638800Updated Jun 10, 2026

Phase 1 Clinical Study of GenSci155 Injection in Healthy Adults

A Phase 1 interventional study of GenSci155 Injection and Placebo in Healthy Adult Trial Participants, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, single and multiple intravenous ascending dose clinical study to evaluate the safety, tolerability, PK, immunogenicity, and biomarker characteristics of GenSci155 after a single or multiple intravenous injection in healthy Chinese adult trial participants.

02

Conditions studied

  • Healthy Adult Trial Participants

Keywords

  • Healthy Volunteers
  • GenSci155
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.Healthy adult male or female trial participants, aged between 18 and 60 years (inclusive) Male body weight ≥ 50 kg and female body weight ≥ 45 kg; (BMI) between 19 and 28 kg/m² (inclusive) at screening 3.In good general condition as determined by medical history, physical examination, vital signs, , laboratory tests, infectious diseases screening and urine drug screening with no abnormalities as judged by the investigator .

4.Female trial participants must have a negative pregnancy test results at screening and baseline.

5.Male and female trial participants of must agree to use non-pharmacological from screening until 3 months after the last dose. From the time of signing the ICF until 3 months after the last dose, they must have no plans for conception, sperm donation, egg donation, or egg cryopreservation. Female trial participants must have had no unprotected sexual intercourse within 14 days prior to screening.

6.Trial participants must voluntarily sign the ICF, be able to understand and comply with the requirements of this trial protocol, and complete scheduled follow-up visits in a timely manner.

Exclusion criteria

Exclusion Criteria:

  1. History of to IGF-1 agents or their ingredients; or a history of allergic diathesis or a history of allergic diseases.
  2. History or current presence of hypoglycemia, or recurrent hypoglycemic episodes.
  3. Severe trauma or major surgical procedure within 12 months prior to screening that, in the investigator's judgment, may affect the safety of the trial participants or the interpretation of the study results, or planning to undergo any surgery during the trial period.
  4. Blood loss or donation exceeding 400 mL within 3 months prior to screening.
  5. Poor peripheral venous access; or physical condition intolerant to sampling.
  6. Presence of significant active systemic or local infection within 4 weeks prior to screening.
  7. Presence of tattoo, sunburn, scar or any other factors at screening that may interfere with the assessment of the injection site at the intended injection area.
  8. History or current presence of any , poorly controlled chronic disease, organ dysfunction, or that, in the investigator's judgment, may affect participant safety or study conduct.
  9. Clinically significant abnormalities in chest x-ray [P-A] at screening.
  10. A positive result at screening for virus antibody (HCV-Ab), antibody (HIV-Ab), treponema pallidum particle agglutination assay (AntiTP ), or virus (HBV) infection
  11. Females who are breastfeeding during the screening period. 12.12-Lead at screening showing any of the following: interval > 450 ms; or heart rate > 100 beats per minute; or any other clinically significant abnormality as determined by the investigator.

13.Any of the following laboratory abnormalities at screening:

  • (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) > (ULN);
  • Total > ULN and considered clinically significant by the investigator.
  • Abnormal (INR) or activated partial thromboplastin time (aPTT) judged to be clinically significant by the investigator.
  • Estimated (eGFR) \< lower limit of normal;
  • Hematology results below the lower reference limit for any of the following and considered clinically significant by the investigator: , count, white blood cell count, absolute lymphocyte count, or .
  • Triglyceride or low-density lipoprotein cholesterol (LDL-C) levels above the upper reference limit and considered clinically significant by the investigator.

    14.Use of any IGF-1 agents within 6 months or 5 half-lives (whichever is longer) prior to screening.

    15.Use of any prescription drugs, over-the-counter medications (including but not limited to vitamins, herbal supplements, dietary supplements, and health products), traditional Chinese medicines, or Chinese patent medicines within 14 days or 5 half-lives (whichever is longer) prior to screening or planned use during the study period.

    16.Participation in another clinical trial within 3 months or 5 half-lives (whichever is longer) prior to screening (except for trial participants who received no intervention), or current participation in any other clinical trial.

    17.Average daily cigarette consumption of ≥ 5 cigarettes within 6 months prior to screening; or unable to refrain from smoking for the duration of the study; or a positive urine cotinine test.

    18.Weekly intake of alcohol exceeding the criteria [defined as >14 units of alcohol on average per week (1 unit of alcohol = 150 mL of wine, 360 mL of beer, or 45 mL of spirits)] within 6 months prior to screening, or inability to stop drinking during the study, or a positive alcohol test.

    19.Positive urine drug screen for substances including, but not limited to: morphine, ketamine, methylenedioxymethamphetamine, methamphetamine, tetrahydrocannabinol, and cocaine.

    20.History of drug abuse; or use of so-called "soft" drugs within 3 months prior to screening; or use of so-called "hard" drugs within 1 year prior to screening.

    21.Any other condition that, in the judgment of the investigator, would make the trial participant unsuitable for participation in this clinical trial.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    GenSci155 Injection

    Drug: GenSci155 Injection

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugGenSci155 Injection

    Part 1 consists of a total of 6 dose cohorts,Part 2 consists of a total of 3 dose cohorts

  • DrugPlacebo

    Part 1 consists of a total of 6 dose cohorts,Part 2 consists of a total of 3 dose cohorts

06

What researchers measure

Primary outcomes

  1. Part1:Incidence and severity of treatment-emergent adverse events (TEAEs)/serious adverse events (SAEs) and other safety measures

    Time frame: From dosing on Day 1 up to 22 days post dose

  2. Part2:Incidence and severity of treatment-emergent adverse events (TEAEs)/serious adverse events (SAEs) and other safety measures

    Time frame: From dosing on Day 1 up to 31 days post dose

Secondary outcomes

  1. Part1:Area under the concentration-time curve (AUC0-t, AUC0-∞,AUC0-τ)of GenSci155

    Time frame: From dosing on Day 1 up to 22 days post dose

  2. Part1:maximum concentration (Cmax)

    Time frame: From dosing on Day 1 up to 22 days post dose

  3. Part1:time to maximum concentration (Tmax)

    Time frame: From dosing on Day 1 up to 22 days post dose

  4. Part1:terminal elimination half-life (t1/2)

    Time frame: From dosing on Day 1 up to 22 days post dose

  5. Part1:clearance (CL)

    Time frame: From dosing on Day 1 up to 22 days post dose

  6. Part1:apparent volume of distribution (Vd)

    Time frame: From dosing on Day 1 up to 22 days post dose

  7. Part2:maximum concentration at steady state (Cmax, ss)

    Time frame: From dosing on Day 1 up to 31 days post dose

  8. Part2:minimum concentration at steady state (Cmin, ss)

    Time frame: From dosing on Day 1 up to 31 days post dose

  9. Part2:time to maximum concentration at steady state (Tmax, ss)

    Time frame: From dosing on Day 1 up to 31 days post dose

  10. Part2:average concentration at steady state (Cav, ss)

    Time frame: From dosing on Day 1 up to 31 days post dose

  11. Part2:area under the concentration-time curve within a dosing interval at steady state (AUC0-τ, ss)

    Time frame: From dosing on Day 1 up to 31 days post dose

  12. Part2:apparent volume of distribution at steady state(Vss)

    Time frame: From dosing on Day 1 up to 31 days post dose

  13. Part2:clearance at steady state (CLss)

    Time frame: From dosing on Day 1 up to 31 days post dose

  14. Part2: t1/2 at steady state (t1/2, ss)

    Time frame: From dosing on Day 1 up to 31 days post dose

  15. Part2: accumulation factor (Rac)

    Time frame: From dosing on Day 1 up to 31 days post dose

  16. Incidence rate, titer, and onset time of positive anti-drug antibody (ADA) and neutralizing antibody (Nab) (if applicable)

    Time frame: From dosing on Day 1 up to 22 or 31 days post dose

Other outcomes

  1. Serum insulin growth factor binding protein-3 (IGFBP-3) and insulin growth factor binding protein-2 (IGFBP-2), and their changes from baseline

    Time frame: From dosing on Day 1 up to 22 or 31 days post dose

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Apr 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jun 10, 2026
StartEst.
Jul 28, 2026
Primary completionEst.
Apr 16, 2027
CompletionEst.
Jul 28, 2027
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07638800
Responsible party
Sponsor
First posted
Jun 10, 2026
Start date
Jul 28, 2026 (estimated)
Primary completion
Apr 16, 2027 (estimated)
Completion
Jul 28, 2027 (estimated)
Last update
Jun 10, 2026

Study contacts

Qingjiang Ni
Contact
niqingjiang@genscigroup.com
+86 17712631723

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion